Treatment of breakthrough and prevention of refractory chemotherapy-induced nausea and vomiting in pediatric cancer patients: Clinical practice guideline update

Priya Patel^{1

2}, Paula D Robinson¹, Robert Phillips³, Christina Baggott⁴, Katie Devine⁵, Paul Gibson^{1

6}, Gregory M T Guilcher^{7

8}, Mark T Holdsworth⁹, Eloise Neumann¹⁰, Andrea D Orsey^{11

12}, Daniela Spinelli¹³, Jennifer Thackray¹⁴, Marianne van de Wetering¹⁵, Sandra Cabral¹, Lillian Sung^{16

17}, L Lee Dupuis^{2

17

18}

Affiliations

¹ Pediatric Oncology Group of Ontario, Toronto, Ontario, Canada.
² Department of Pharmacy, The Hospital for Sick Children, Toronto, Ontario, Canada.
³ Department of Haematology and Oncology, NHS Trust, Leeds Teaching Hospital, Leeds, UK.
⁴ Cancer Clinical Trials Office, Stanford Cancer Institute, Palo Alto, California, USA.
⁵ Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
⁶ Division of Haematology/Oncology, McMaster Children's Hospital, Hamilton, Ontario, Canada.
⁷ Section of Paediatric Oncology and Blood and Marrow Transplant, Alberta Children's Hospital, Calgary, Alberta, Canada.
⁸ Departments of Oncology and Paediatrics, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
⁹ College of Pharmacy, University of New Mexico, Albuquerque, New Mexico, USA.
¹⁰ Birmingham Women's and Children's Hospital, Birmingham, UK.
¹¹ Division of Pediatric Hematology/Oncology, Connecticut Children's Medical Center, Hartford, Connecticut, USA.
¹² Department of Pediatrics, University of Connecticut School of Medicine, Farmington, Connecticut, USA.
¹³ Patient representative.
¹⁴ Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
¹⁵ Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands.
¹⁶ Department of Paediatrics, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
¹⁷ Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
¹⁸ Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.

PMID: 37178438
DOI: 10.1002/pbc.30395

Practice Guideline

Treatment of breakthrough and prevention of refractory chemotherapy-induced nausea and vomiting in pediatric cancer patients: Clinical practice guideline update

Priya Patel et al. Pediatr Blood Cancer. 2023 Aug.

. 2023 Aug;70(8):e30395.

doi: 10.1002/pbc.30395. Epub 2023 May 13.

Authors

Affiliations

¹ Pediatric Oncology Group of Ontario, Toronto, Ontario, Canada.
² Department of Pharmacy, The Hospital for Sick Children, Toronto, Ontario, Canada.
³ Department of Haematology and Oncology, NHS Trust, Leeds Teaching Hospital, Leeds, UK.
⁴ Cancer Clinical Trials Office, Stanford Cancer Institute, Palo Alto, California, USA.
⁵ Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
⁶ Division of Haematology/Oncology, McMaster Children's Hospital, Hamilton, Ontario, Canada.
⁷ Section of Paediatric Oncology and Blood and Marrow Transplant, Alberta Children's Hospital, Calgary, Alberta, Canada.
⁸ Departments of Oncology and Paediatrics, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
⁹ College of Pharmacy, University of New Mexico, Albuquerque, New Mexico, USA.
¹⁰ Birmingham Women's and Children's Hospital, Birmingham, UK.
¹¹ Division of Pediatric Hematology/Oncology, Connecticut Children's Medical Center, Hartford, Connecticut, USA.
¹² Department of Pediatrics, University of Connecticut School of Medicine, Farmington, Connecticut, USA.
¹³ Patient representative.
¹⁴ Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
¹⁵ Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands.
¹⁶ Department of Paediatrics, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
¹⁷ Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
¹⁸ Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.

PMID: 37178438
DOI: 10.1002/pbc.30395

Abstract

This clinical practice guideline update provides recommendations for treating breakthrough chemotherapy-induced nausea and vomiting (CINV) and preventing refractory CINV in pediatric patients. Two systematic reviews of randomized controlled trials in adult and pediatric patients informed the recommendations. In patients with breakthrough CINV, escalation of antiemetic agents to those recommended for chemotherapy of the next higher level of emetogenic risk is strongly recommended. A similar recommendation to escalate therapy is made to prevent refractory CINV in patients who did not experience complete breakthrough CINV control and are receiving minimally or low emetogenic chemotherapy. A strong recommendation to use antiemetic agents that controlled breakthrough CINV for the prevention of refractory CINV is also made.

Keywords: chemotherapy-induced nausea and vomiting; guideline; pediatric oncology; supportive care.

PubMed Disclaimer

Update of

Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer.
Flank J, Robinson PD, Holdsworth M, Phillips R, Portwine C, Gibson P, Maan C, Stefin N, Sung L, Dupuis LL. Flank J, et al. Pediatr Blood Cancer. 2016 Jul;63(7):1144-51. doi: 10.1002/pbc.25955. Epub 2016 Mar 9. Pediatr Blood Cancer. 2016. Update in: Pediatr Blood Cancer. 2023 Aug;70(8):e30395. doi: 10.1002/pbc.30395. PMID: 26960036 Updated. Review.

References

REFERENCES

1. Patel P, Robinson PD, Cohen M, et al. Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: a clinical practice guideline. Pediatr Blood Cancer. 2022;69(12):e30001.
1. Flank J, Robinson PD, Holdsworth M, et al. Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer. Pediatr Blood Cancer. 2016;63(7):1144-1151.
1. Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: a clinical practice guideline. Pediatr Blood Cancer. 2019;66(5):e27646.
1. Patel P, Robinson PD, Devine KA, et al. Prevention and treatment of anticipatory chemotherapy-induced nausea and vomiting in pediatric cancer patients and hematopoietic stem cell recipients: clinical practice guideline update. Pediatr Blood Cancer. 2021;68(5):e28947.
1. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Wiley

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Treatment of breakthrough and prevention of refractory chemotherapy-induced nausea and vomiting in pediatric cancer patients: Clinical practice guideline update

Affiliations

Treatment of breakthrough and prevention of refractory chemotherapy-induced nausea and vomiting in pediatric cancer patients: Clinical practice guideline update

Authors

Affiliations

Abstract

Update of

References

REFERENCES

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources